Revenue
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biomarin Pharmaceutical Inc (BMRN)
Price$65.51Cached quote
Net income
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B | $1.70B | $1.49B | $1.31B | $1.12B | $889.9M | $749.3M | $548.5M | $500.7M | $441.4M | $376.3M | $324.7M | $296.5M |
| Gross profit | $2.50B | $2.27B | $1.89B | $1.59B | $1.38B | $1.34B | $1.34B | $1.18B | $1.07B | $907.2M | $737.9M | $627.0M | $460.1M | $408.9M | $357.3M | $306.0M | $258.7M | $244.0M |
| Gross margin | 77.73% | 79.67% | 78.01% | 76.00% | 74.52% | 71.82% | 78.91% | 78.86% | 81.59% | 81.23% | 82.92% | 83.68% | 83.88% | 81.66% | 80.96% | 81.32% | 79.70% | 82.29% |
| Research & development | $921.9M | $747.2M | $746.8M | $649.6M | $628.8M | $628.1M | $715.0M | $696.3M | $610.8M | $661.9M | $634.8M | $461.5M | $354.8M | $302.2M | $214.4M | $147.3M | $115.1M | $93.3M |
| Operating expenses | $2.81B | $2.37B | $2.23B | $1.94B | $1.93B | $1.90B | $1.80B | $1.61B | $1.33B | $1.92B | $1.00B | $842.2M | $704.5M | $610.9M | $475.2M | $375.7M | $308.2M | $256.7M |
| Operating income | $409.5M | $484.2M | $185.8M | $161.0M | −$82.3M | −$43.4M | −$100.5M | −$123.5M | −$14.7M | −$803.4M | −$110.7M | −$92.9M | −$156.0M | −$110.2M | −$33.9M | $544,000 | $16.4M | $39.8M |
| Operating margin | 12.71% | 16.97% | 7.68% | 7.68% | −4.46% | −2.33% | −5.90% | −8.28% | −1.12% | −71.94% | −12.44% | −12.40% | −28.44% | −22.01% | −7.68% | 0.14% | 5.06% | 13.41% |
| EBITDA | $489.0M | $580.6M | $290.2M | $262.9M | $25.7M | $61.7M | $4.8M | −$27.9M | $73.2M | −$706.5M | −$63.5M | −$47.0M | −$120.0M | −$65.9M | $1.2M | $28.3M | $37.4M | $57.4M |
| EBITDA margin | 15.18% | 20.35% | 11.99% | 12.54% | 1.39% | 3.32% | 0.28% | −1.87% | 5.57% | −63.26% | −7.14% | −6.28% | −21.88% | −13.16% | 0.26% | 7.52% | 11.52% | 19.35% |
| Net income | $348.9M | $426.9M | $167.6M | $141.6M | −$64.1M | $854.0M | −$23.8M | −$77.2M | −$117.0M | −$630.2M | −$171.8M | −$134.0M | −$176.4M | −$114.3M | −$53.8M | $205.8M | −$488,000 | $30.8M |
| Net profit margin | 10.83% | 14.96% | 6.93% | 6.75% | −3.47% | 45.90% | −1.40% | −5.18% | −8.91% | −56.43% | −19.31% | −17.88% | −32.15% | −22.84% | −12.20% | 54.70% | −0.15% | 10.40% |
| Basic EPSper basic share | $1.82 | $2.25 | $0.89 | $0.76 | -$0.35 | $4.72 | -$0.13 | -$0.44 | -$0.67 | -$3.80 | -$1.07 | -$0.92 | -$1.28 | -$0.95 | -$0.48 | $2.00 | $0.00 | $0.31 |
| Diluted EPSper diluted share | $1.80 | $2.21 | $0.87 | $0.75 | -$0.35 | $4.50 | -$0.13 | -$0.44 | -$0.67 | -$3.81 | -$1.07 | -$0.92 | -$1.28 | -$0.95 | -$0.48 | $1.73 | $0.00 | $0.29 |
Owners
Reported shareholders
10.56%of listed shares
BlackRock, Inc.20.45M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 10.56%20.45M shares |
Dodge & Cox | 7.67%14.84M shares |
PRIMECAP MANAGEMENT CO/CA/ | 7.33%14.19M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.52%8.74M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 4.47%8.65M shares |
NORGES BANK | 4.24%8.21M shares |
STATE STREET CORP | 4.03%7.8M shares |
VIKING GLOBAL INVESTORS LP | 3.94%7.62M shares |
Vestal Point Capital, LP | 3.11%6.03M shares |
AQR CAPITAL MANAGEMENT LLC | 2.94%5.7M shares |
FMR LLC | 2.49%4.82M shares |
DIMENSIONAL FUND ADVISORS LP | 2.11%4.08M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.02%3.91M shares |
Assenagon Asset Management S.A. | 1.82%3.52M shares |
Capital Research Global Investors | 1.81%3.5M shares |
Deep Track Capital, LP | 1.71%3.31M shares |
MILLENNIUM MANAGEMENT LLC | 1.07%2.07M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.83%1.62M shares |
FIRST TRUST ADVISORS LP | 0.83%1.61M shares |
NORTHERN TRUST CORP | 0.81%1.56M shares |
Percentages use 193.54M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 7, 2026Form 4 | Friberg Gregory REVP, Chief R&D Officer | SellCommon Stock | 3.3K | $53.85 | $176.7K | 51.8K |
| Mar 11, 2026Form 4 | Guyer Charles GregEVP, Chief Technical Officer | SellCommon Stock | 16.5K | $60.46 | $996.7K | 80.0K |
| Feb 26, 2026Form 4 | Friberg Gregory REVP, Chief R&D Officer | SellCommon Stock | 6.3K | $60.38 | $382.0K | 37.6K |
| Feb 26, 2026Form 4 | Davis George EricEVP, Chief Legal Officer | SellCommon Stock | 26.1K | $61.36 | $1.60M | 72.5K |
| May 20, 2025Form 4 · 10b5-1 | Burkhart ErinGVP, Chief Accounting Officer | SellCommon Stock | 1.8K | $59.31 | $105.9K | 14.2K |